Halla W. Reinert
Environment Agency(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Neuroscience and Neuropharmacology Research, Monoclonal and Polyclonal Antibodies Research, Neuroblastoma Research and Treatments
Most-Cited Works
- → Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine(2018)124 cited
- → Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer(2018)47 cited
- → Upregulation of mucin glycoprotein MUC1 in the progression to esophageal adenocarcinoma and therapeutic potential with a targeted photoactive antibody-drug conjugate(2017)25 cited
- → A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy(2016)16 cited
- → Using antibody directed phototherapy to target oesophageal adenocarcinoma with heterogeneous HER2 expression(2018)13 cited
- → Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors(2017)5 cited
- → Seroprevalence of SARS-CoV-2–Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020(2021)3 cited
- → Supplementary Methods from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer(2023)
- → Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer(2023)
- → Supplementary Data from Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers(2023)